Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -374,339 | -312,627 | -51,135 | 26,941 | 53,408 |
| Depreciation Amortization | 21,245 | 10,691 | 38,191 | 25,818 | 17,225 |
| Income taxes - deferred | -130,661 | -128,703 | 36,660 | 35,759 | 19,310 |
| Accounts receivable | -18,462 | -48,834 | 39,912 | 43,538 | -2,483 |
| Accounts payable and accrued liabilities | -53,374 | -40,571 | 14,892 | 1,359 | -15,313 |
| Other Working Capital | -86,870 | -80,771 | -11,817 | -33,651 | -110,074 |
| Other Operating Activity | 575,756 | 535,037 | 201,138 | 127,518 | 159,248 |
| Operating Cash Flow | $-66,705 | $-65,778 | $267,841 | $227,282 | $121,321 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -18,408 | -16,607 | -71,140 | -43,094 | -21,698 |
| Purchase Of Investment | -898,292 | -458,499 | -1,706,655 | -1,309,044 | -778,089 |
| Sale Of Investment | 830,906 | 430,535 | 1,367,927 | 941,314 | 502,188 |
| Other Investing Activity | 43,507 | 6,975 | -15,949 | -22,149 | -4,146 |
| Investing Cash Flow | $-42,287 | $-37,596 | $-425,817 | $-432,973 | $-301,745 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -12,404 | -10,096 | -2,615 | -2,408 | 0 |
| Common Stock Issued | 207,872 | 21,670 | 191,721 | 174,950 | 158,003 |
| Other Financing Activity | -44,115 | -17,709 | -16,902 | -5,175 | 1,214 |
| Financing Cash Flow | $151,353 | $-6,135 | $172,204 | $167,367 | $159,217 |
| Exchange Rate Effect | -521 | -799 | -141 | -110 | -52 |
| Beginning Cash Position | 489,407 | 489,407 | 475,320 | 475,320 | 475,320 |
| End Cash Position | 531,247 | 379,099 | 489,407 | 436,886 | 454,061 |
| Net Cash Flow | $41,840 | $-110,308 | $14,087 | $-38,434 | $-21,259 |
| Free Cash Flow | |||||
| Operating Cash Flow | -66,705 | -65,778 | 267,841 | 227,282 | 121,321 |
| Capital Expenditure | -18,408 | -16,607 | -71,140 | -43,094 | -21,698 |
| Free Cash Flow | -85,113 | -82,385 | 196,701 | 184,188 | 99,623 |